NYSE:KDMNKadmon Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kadmon Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.23 -0.02 (-0.47 %) (As of 08/10/2020 03:07 PM ET) Add Compare Share Today's Range$4.05Now: $4.23▼$4.3050-Day Range$3.57MA: $4.34▼$5.2652-Week Range$2.04Now: $4.23▼$5.50Volume95,624 shsAverage Volume2.49 million shsMarket Capitalization$723.92 millionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingKadmon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.60, Kadmon has a potential upside of 199.3% from its current price of $4.21.Amount of Analyst CoverageKadmon has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesKadmon has received 260 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKadmon has received 238 “underperform” votes. (Add your “underperform” vote.)Community SentimentKadmon has received 52.21% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote “Outperform” if you believe KDMN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKadmon does not currently pay a dividend.Dividend GrowthKadmon does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kadmon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.95% of the stock of Kadmon is held by insiders.Percentage Held by Institutions87.38% of the stock of Kadmon is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kadmon are expected to grow in the coming year, from ($0.60) to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kadmon is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kadmon is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKadmon has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:KDMN Previous Symbol CUSIPN/A CIK1557142 Webwww.kadmon.com Phone833-900-5366Debt Debt-to-Equity Ratio0.16 Current Ratio6.15 Quick Ratio6.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.09 million Price / Sales142.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book4.45Profitability EPS (Most Recent Fiscal Year)($0.74) Net Income$-61,370,000.00 Net Margins-1,105.49% Return on Equity-138.49% Return on Assets-68.21%Miscellaneous Employees116 Outstanding Shares171,140,000Market Cap$723.92 million Next Earnings Date8/10/2020 (Estimated) OptionableOptionable $4.23 -0.02 (-0.47 %) (As of 08/10/2020 03:07 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KDMN News and Ratings via Email Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter. Kadmon (NYSE:KDMN) Frequently Asked Questions How has Kadmon's stock been impacted by COVID-19 (Coronavirus)? Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KDMN shares have increased by 21.6% and is now trading at $4.23. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Kadmon? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kadmon. When is Kadmon's next earnings date? Kadmon is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Kadmon. How were Kadmon's earnings last quarter? Kadmon Holdings Inc (NYSE:KDMN) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. Kadmon had a negative return on equity of 138.49% and a negative net margin of 1,105.49%. View Kadmon's earnings history. What price target have analysts set for KDMN? 5 brokers have issued twelve-month price objectives for Kadmon's shares. Their forecasts range from $8.00 to $25.00. On average, they expect Kadmon's stock price to reach $12.60 in the next twelve months. This suggests a possible upside of 197.9% from the stock's current price. View analysts' price targets for Kadmon. Has Kadmon been receiving favorable news coverage? News articles about KDMN stock have trended very positive on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kadmon earned a news sentiment score of 3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Kadmon. Who are some of Kadmon's key competitors? Some companies that are related to Kadmon include Principia Biopharma (PRNB), SAGE Therapeutics (SAGE), CytoDyn (CYDY), Amarin (AMRN), Deciphera Pharmaceuticals (DCPH), Pacira Biosciences (PCRX), Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), Ligand Pharmaceuticals (LGND), Uniqure (QURE) and Xencor (XNCR). View all competitors. What other stocks do shareholders of Kadmon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Iovance Biotherapeutics (IOVA), Applied Materials (AMAT), Biocept (BIOC), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and Global Blood Therapeutics (GBT). Who are Kadmon's key executives? Kadmon's management team includes the following people: Dr. Harlan W. Waksal, Pres, CEO & Director (Age 66)Mr. Steven Meehan, Exec. VP & CFO (Age 54)Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 51)Ms. Cynthia L. Schwalm, Director (Age 59)Mr. Kyle Carver, Controller & Principal Accounting Officer When did Kadmon IPO? (KDMN) raised $101 million in an initial public offering (IPO) on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers. What is Kadmon's stock symbol? Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN." Who are Kadmon's major shareholders? Kadmon's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.72%), Swiss National Bank (0.17%), Russell Investments Group Ltd. (0.13%), Leap Investments LP (0.06%), Rafferty Asset Management LLC (0.05%) and Principal Financial Group Inc. (0.03%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc. View institutional ownership trends for Kadmon. Which major investors are selling Kadmon stock? KDMN stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and SG Americas Securities LLC. View insider buying and selling activity for Kadmon. Which major investors are buying Kadmon stock? KDMN stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Swiss National Bank, Russell Investments Group Ltd., Leap Investments LP, Rafferty Asset Management LLC, Principal Financial Group Inc., Arizona State Retirement System, and Hancock Whitney Corp. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc. View insider buying and selling activity for Kadmon. How do I buy shares of Kadmon? Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kadmon's stock price today? One share of KDMN stock can currently be purchased for approximately $4.23. How big of a company is Kadmon? Kadmon has a market capitalization of $723.92 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe. What is Kadmon's official website? The official website for Kadmon is www.kadmon.com. How can I contact Kadmon? Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
